statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced...

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

VTGN's total volume now sits at 921.6K. The +2.10% price change was insignificant, leaving IBM's price at $5.39...

The volume for VistaGen Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 218% of the 65-Day Volume Moving Average

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Key Insights The considerable ownership by individual investors in Vistagen Therapeutics indicates that they...

Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners are individual investors who got richer after stock soared 25% last week

This is a signal that VTGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

VistaGen Therapeutics (VTGN, $5.28) RSI Indicator left the overbought zone on March 28, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

VistaGen Therapeutics (VTGN, $5.28) price moved above its 50-day Moving Average on March 28, 2024

This price move could be a signal that VTGN may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

VistaGen Therapeutics (VTGN, $4.6) price may drop as it broke higher Bollinger Band on Mar 27, 2024

This indicator may be signaling VTGN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

VistaGen Therapeutics (VTGN, $4.28) entered Uptrend as Momentum indicator ascends above 0 level on Mar 25, 2024

For the last three days, A.I.dvisor has detected that VTGN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

VistaGen Therapeutics (VTGN, $4.17) Aroon Indicator entered a Downtrend on March 22, 2024.

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Watchers	18,259
52-Wk Low	$1.62
52-Wk High	$24.71

Volume	97,056.00
52-Wk High	$24.71
52-Wk Low	$1.62

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.36	--	--	N/A
Q3'23	-$0.30	-$0.22	27.27%	BEAT
Q2'23	-$0.68	-$0.66	2.94%	BEAT
Q1'23	-$0.86	-$0.94	-9.30%	MISSED
Q4'22	-$1.50	-$1.61	-7.33%	MISSED

VTGN VistaGen Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals